Funding for this research was provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Received: 6 December 2021
Accepted: 16 September 2022
First Online: 29 September 2022
: Data used in this study are de-identified and comply with the requirements of the Health Insurance Portability and Accountability Act; therefore, no institutional review board approval was needed, per Title 45 of CFR, Part 46.101(b)(4) (ExternalRef removed).
: Not applicable.
: JS is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. AU is an employee of Lundbeck LLC. PM is an independent consultant and was an external consultant at Lundbeck A/S at the time the study was conducted. Otsuka Pharmaceutical Development & Commercialization, Inc. funded the development and conduct of this study and manuscript.PGS, MC, ES, and AG are employees of Analysis Group, Inc. YL was an employee of Analysis Group, Inc. at the time the study was conducted. Analysis Group, Inc. is a consulting company that has provided paid consulting services to Otsuka Pharmaceutical Development & Commercialization, Inc.LLD has received consulting fees from Boehringer Ingelheim, Janssen, Lundbeck, Otsuka, and Signant Health, and research funding or materials from Alkermes, Allergan, Aptinyx, Avanir, DoD, SAMHSA, Social Finance, Tonix, VA, and Westat.